首站-论文投稿智能助手
典型文献
Kif4A mediates resistance to neoadjuvant chemoradiotherapy in patients with advanced colorectal cancer via regulating DNA damage response
文献摘要:
More and more patients with advanced colorectal cancer(CRC)have benefited from surgical resection or ablation following neoadjuvant chemoradiotherapy(nCRT),but nCRT may be ineffective and have potential risks to some patients.Therefore,it is necessary to discover effective biomarkers for predicting the nCRT efficacy in CRC patients.Chromokinesin Kif4A plays a critical role in mitosis,DNA damage repair and tumorigenesis,but its relationship with nCRT efficacy in advanced CRC remains unclear.Here,we find that Kif4A expression in pretreated tumor tissue is positively correlated with poorer tumor regression after receiving nCRT(P=0.005).Knockdown of endogenous Kif4A causes an increased sensitivity of CRC cells to chemotherapeutic drugs 5-fluorouracil(5-FU)and Cisplatin(DDP),while overexpression of Kif4A enhances resistance of CRC cells to the chemotherapeutic drugs.Furthermore,depending on its motor domain and tail domain,Kif4A regulates DNA damage response(DDR)induced by 5-FU or DDP treatment in CRC cells.In conclusion,we demonstrate that Kif4A may be a potential independent biomarker for predicting the nCRT efficacy in advanced CRC patients,and Kif4A regulates chemosensitivity of CRC cells through controlling DDR.
文献关键词:
作者姓名:
Rui Zhang;Shuanghui Liu;Bojiang Gong;Wenran Xie;Youjuan Zhao;Liang Xu;Yi Zheng;Shengnan Jin;Chunming Ding;Chang Xu;Zhixiong Dong
作者机构:
Zhejiang Provincial Key Laboratory of Medical Genetics,Key Laboratory of Laboratory Medicine,Ministry of Education,School of Laboratory Medicine and Life Science,Wenzhou Medical University,Wenzhou 325000,China;Department of Colorectal Surgery,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China
引用格式:
[1]Rui Zhang;Shuanghui Liu;Bojiang Gong;Wenran Xie;Youjuan Zhao;Liang Xu;Yi Zheng;Shengnan Jin;Chunming Ding;Chang Xu;Zhixiong Dong-.Kif4A mediates resistance to neoadjuvant chemoradiotherapy in patients with advanced colorectal cancer via regulating DNA damage response)[J].生物化学与生物物理学报(英文版),2022(07):940-951
A类:
Kif4A,Chromokinesin,chemosensitivity
B类:
mediates,resistance,neoadjuvant,chemoradiotherapy,patients,advanced,colorectal,cancer,via,regulating,damage,response,More,CRC,have,benefited,from,surgical,resection,ablation,following,nCRT,but,may,ineffective,potential,risks,some,Therefore,necessary,discover,biomarkers,predicting,efficacy,plays,critical,role,mitosis,repair,tumorigenesis,its,relationship,remains,unclear,Here,we,find,that,pretreated,tissue,positively,correlated,poorer,regression,after,receiving,Knockdown,endogenous,causes,increased,cells,chemotherapeutic,drugs,fluorouracil,FU,Cisplatin,DDP,while,overexpression,enhances,Furthermore,depending,motor,domain,tail,regulates,DDR,induced,by,treatment,In,conclusion,demonstrate,independent,through,controlling
AB值:
0.478485
相似文献
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
Yujiao Wang;Xi Jiao;Shuang Li;Huan Chen;Xin Wei;Chang Liu;Jifang Gong;Xiaotian Zhang;Xicheng Wang;Zhi Peng;Changsong Qi;Zhenghang Wang;Yanni Wang;Na Zhuo;Jianling Zou;Henghui Zhang;Jian Li;Lin Shen;Zhihao Lu-Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Gastric&Colorectal Surgery,The First Hospital of Jilin University,Changchun 130021,China;Genecast Precision Medicine Technology Institute,Beijing 100192,China;Life Sciences Institute,Zhejiang University,Hangzhou 310058,China;Institute of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China
Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer
Junru Feng;Hui Lu;Wenhao Ma;Wenjing Tian;Zhuan Lu;Hongying Yang;Yongping Cai;Pengfei Cai;Yuchen Sun;Zilong Zhou;Jiaqian Feng;Jiazhong Deng;Ying Shu;Kun Qu;Weidong Jia;Ping Gao;Huafeng Zhang-Anhui Key Laboratory of Hepatopancreatobiliary Surgery,Department of General Surgery,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230027,China;Hefei National Laboratory for Physical Sciences at Microscale,The Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease,School of Basic Medical Sciences,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230027,China;Shenzhen People's Hospital,Second Clinical Medical College of Jinan University,First Affiliated Hospital of Southern University of Science and Technology,Shenzhen 518000,China;Department of Pathology,School of Medicine,Anhui Medical University,Hefei 230032,China;School of Medicine and Institutes for Life Sciences,South China University of Technology,Guangzhou 510006,China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Stratifin promotes renal dysfunction in ischemic and nephrotoxic AKI mouse models via enhancing RIPK3-mediated necroptosis
Fang Wang;Jia-nan Wang;Xiao-yan He;Xiao-guo Suo;Chao Li;Wei-jian Ni;Yu-ting Cai;Yuan He;Xin-yun Fang;Yu-hang Dong;Tian Xing;Ya-ru Yang;Feng Zhang;Xiang Zhong;Hong-mei Zang;Ming-ming Liu;Jun Li;Xiao-ming Meng;Juan Jin-Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,School of Pharmacy,Anhui Medical University,The Key Laboratory of Anti-inflammatory of Immune Medicines,Ministry of Education,Hefei 230032,China;Department of Pharmacy,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Hospital of Stomatology,Anhui Medical University,Key Laboratory of Oral Diseases Research of Anhui Province,Hefei 230032,China;Department of Pharmacy,Changzheng Hospital,Naval Medical University,Shanghai 200003,China;Department of Nephrology,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。